scholarly journals Expression of the Major Core Structural Protein (VP7) of Bluetongue Virus, by a Recombinant Capripox Virus, Provides Partial Protection of Sheep against a Virulent Heterotypic Bluetongue Virus Challenge

Virology ◽  
1996 ◽  
Vol 220 (1) ◽  
pp. 227-231 ◽  
Author(s):  
A.M. WADE-EVANS ◽  
C.H. ROMERO ◽  
P. MELLOR ◽  
H. TAKAMATSU ◽  
J. ANDERSON ◽  
...  
Keyword(s):  
Bluetongue Virus ◽  
Structural Protein ◽  
Partial Protection ◽  
Virus Challenge

scholarly journals The Combined Expression of the Non-structural Protein NS1 and the N-Terminal Half of NS2 (NS2 1-180 ) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge

2021 ◽  
Author(s):  
Sergio Utrilla-Trigo ◽  
Luis Jiménez-Cabello ◽  
Eva Calvo-Pinilla ◽  
Alejandro Marín-López ◽  
Gema Lorenzo ◽  
...  
Keyword(s):  
Bluetongue Virus ◽  
Booster Dose ◽  
Vaccination Strategy ◽  
Current Phase ◽  
Ns1 Protein ◽  
Structural Protein ◽  
Virus Challenge ◽  
Cell Responses ◽  
Lethal Infection ◽  
Phase I And Ii

Bluetongue, caused by bluetongue virus (BTV), is a widespread arthropod-borne disease of ruminants that entails a recurrent threat to the primary sector of developed and developing countries. In this work, we report MVA and ChAdOx1-vectored vaccines designed to simultaneously express the immunogenic NS1 protein and/or NS2-Nt, the N-terminal half of protein NS2 (NS2 1-180 ). A single dose of MVA or ChAdOx1 expressing NS1-NS2-Nt improved the protection conferred by NS1 alone in IFNAR(-/-) mice. Moreover, mice immunized with ChAdOx1/MVA-NS1, ChAdOx1/MVA-NS2-Nt or ChAdOx1/MVA-NS1-NS2-Nt developed strong cytotoxic CD8+ T-cell responses against NS1, NS2-Nt or both proteins and were fully protected against a lethal infection with BTV serotypes 1, 4 and 8. Furthermore, although a single immunization with ChAdOx1-NS1-NS2-Nt partially protected sheep against BTV-4, the administration of a booster dose of MVA-NS1-NS2-Nt promoted a faster viral clearance, reduction of the period and level of viremia and also protected from the pathology produced by BTV infection. Importance Current BTV vaccines are effective but they do not allow to distinguish between vaccinated and infected animals (DIVA strategy) and are serotype specific. In this work we have develop a DIVA multiserotype vaccination strategy based on adenoviral (ChAdOx1) and MVA vaccine vectors, the most widely used in current phase I and II clinical trials, and the conserved non-structural BTV proteins NS1 and NS2. This immunization strategy solves the major drawbacks of the current marketed vaccines.

Bluetongue virus non-structural protein 3 (NS3) and NS4 coordinatively antagonize type Ⅰ interferon signaling by targeting STAT1

2021 ◽  
Vol 254 ◽  
pp. 108986
Author(s):  
Zhuoran Li ◽  
Danfeng Lu ◽  
Heng Yang ◽  
Zhuoyue Li ◽  
Pei Zhu ◽  
...  
Keyword(s):  
Bluetongue Virus ◽  
Interferon Signaling ◽  
Structural Protein

scholarly journals Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and May Elicit NS1-Specific Antibody Responses in Vaccinated Individuals

Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 81 ◽  
Author(s):  
Jiri Salat ◽  
Kamil Mikulasek ◽  
Osmany Larralde ◽  
Petra Pokorna Formanova ◽  
Ales Chrdle ◽  
...  
Keyword(s):  
Viral Envelope ◽  
Structural Protein ◽  
Specific Antibodies ◽  
Virus Challenge ◽  
Ms Analysis ◽  
Tick Borne Encephalitis ◽  
Ns1 Antigen ◽  
The Mean ◽  
Tick Borne Encephalitis Virus ◽  
Viral Surface

Vaccination against tick-borne encephalitis (TBE) is based on the use of formalin-inactivated, culture-derived whole-virus vaccines. Immune response following vaccination is primarily directed to the viral envelope (E) protein, the major viral surface antigen. In Europe, two TBE vaccines are available in adult and pediatric formulations, namely FSME-IMMUN® (Pfizer) and Encepur® (GlaxoSmithKline). Herein, we analyzed the content of these vaccines using mass spectrometry (MS). The MS analysis revealed that the Encepur vaccine contains not only proteins of the whole virus particle, but also viral non-structural protein 1 (NS1). MS analysis of the FSME-IMMUN vaccine failed due to the high content of human serum albumin used as a stabilizer in the vaccine. However, the presence of NS1 in FSME-IMMUN was confirmed by immunization of mice with six doses of this vaccine, which led to a robust anti-NS1 antibody response. NS1-specific Western blot analysis also detected anti-NS1 antibodies in sera of humans who received multiple doses of either of these two vaccines; however, most vaccinees who received ≤3 doses were negative for NS1-specific antibodies. The contribution of NS1-specific antibodies to protection against TBE was demonstrated by immunization of mice with purified NS1 antigen, which led to a significant (p < 0.01) prolongation of the mean survival time after lethal virus challenge. This indicates that stimulation of anti-NS1 immunity by the TBE vaccines may increase their protective effect.

scholarly journals Identification and Characterization of a Novel Non-Structural Protein of Bluetongue Virus

2011 ◽  
Vol 7 (12) ◽  
pp. e1002477 ◽  
Author(s):  
Maxime Ratinier ◽  
Marco Caporale ◽  
Matthew Golder ◽  
Giulia Franzoni ◽  
Kathryn Allan ◽  
...  
Keyword(s):  
Bluetongue Virus ◽  
Structural Protein ◽  
Identification And Characterization

scholarly journals Vaccination With Recombinant Adenoviruses Expressing the Bluetongue Virus Subunits VP7 and VP2 Provides Protection Against Heterologous Virus Challenge

2021 ◽  
Vol 8 ◽  
Author(s):  
José Manuel Rojas ◽  
Diego Barba-Moreno ◽  
Miguel Avia ◽  
Noemí Sevilla ◽  
Verónica Martín
Keyword(s):  
T Cell ◽  
Bluetongue Virus ◽  
Neutralizing Antibodies ◽  
Inner Core ◽  
Core Protein ◽  
T Cell Responses ◽  
Outer Core ◽  
Economic Losses ◽  
Virus Challenge ◽  
Cell Responses

Bluetongue virus (BTV) is the causative agent of a disease that affects domestic and wild ruminants and leads to critical economic losses. BTV is an arbovirus from the Reoviridae family that is typically transmitted by the bite of infected Culicoides midges. BTV possesses multiple serotypes (up to 28 have been described), and immunity to one serotype offers little cross-protection to other serotypes. The design of vaccines that provide protection across multiple serotypes is therefore highly desirable to control this disease. We previously reported that a recombinant replication-defective human adenovirus serotype 5 (Ad5) that expresses the VP7 inner core protein of BTV serotype 8 (Ad5VP7-8) induced T-cell responses and provided protection. In the present work, we evaluated as BTV vaccine the combination of Ad5VP7-8 with another recombinant Ad5 that expresses the outer core protein VP2 from BTV-1 (Ad5VP2-1). The combination of Ad5VP2-1 and Ad5VP7-8 protected against homologous BTV challenge (BTV-1 and BTV-8) and partially against heterologous BTV-4 in a murine model. Cross-reactive anti-BTV immunoglobulin G (IgG) were detected in immunized animals, but no significant titers of neutralizing antibodies were elicited. The Ad5VP7-8 immunization induced T-cell responses that recognized all three serotypes tested in this study and primed cytotoxic T lymphocytes specific for VP7. This study further confirms that targeting antigenic determinant shared by several BTV serotypes using cellular immunity could help develop multiserotype BTV vaccines.

scholarly journals An Attenuated Zika Virus Encoding Non-Glycosylated Envelope (E) and Non-Structural Protein 1 (NS1) Confers Complete Protection against Lethal Challenge in a Mouse Model

Vaccines ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 112 ◽  
Author(s):  
Arun S. Annamalai ◽  
Aryamav Pattnaik ◽  
Bikash R. Sahoo ◽  
Zack P. Guinn ◽  
Brianna L. Bullard ◽  
...  
Keyword(s):  
Zika Virus ◽  
Structural Protein ◽  
Complete Protection ◽  
Lethal Challenge ◽  
Live Virus ◽  
Virus Challenge ◽  
Glycosylation Sites ◽  
Viral Vaccine ◽  
Asian Lineage ◽  
Congenital Microcephaly

Zika virus (ZIKV), a mosquito-transmitted flavivirus, emerged in the last decade causing serious human diseases, including congenital microcephaly in newborns and Guillain-Barré syndrome in adults. Although many vaccine platforms are at various stages of development, no licensed vaccines are currently available. Previously, we described a mutant MR766 ZIKV (m2MR) bearing an E protein mutation (N154A) that prevented its glycosylation, resulting in attenuation and defective neuroinvasion. To further attenuate m2MR for its potential use as a live viral vaccine, we incorporated additional mutations into m2MR by substituting the asparagine residues in the glycosylation sites (N130 and N207) of NS1 with alanine residues. Examination of pathogenic properties revealed that the virus (m5MR) carrying mutations in E (N154A) and NS1 (N130A and N207A) was fully attenuated with no disease signs in infected mice, inducing high levels of humoral and cell-mediated immune responses, and protecting mice from subsequent lethal virus challenge. Furthermore, passive transfer of sera from m5MR-infected mice into naïve animals resulted in complete protection from lethal challenge. The immune sera from m5MR-infected animals neutralized both African and Asian lineage viruses equally well, suggesting that m5MR virus could be developed as a potentially broad live virus vaccine candidate.

Sign in / Sign up

Export Citation Format

Share Document